Korea's LG Life Sciences Signs Deal With China's Double-Crane Covering DPP-4 Inhibitor Gemigliptin

SEOUL - South Korea's LG Life Sciences has signed an exclusive license, supply and distribution agreement with China's Double-Crane Pharmaceutical, under which the Chinese company will sell - inside China - LG's DPP-4 inhibitor Gemigliptin for treatment of diabetes